New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 150ug; ribavirin 200mg;   - combination - 200mg+150µg(clearclick) - active: peginterferon alfa-2b 150ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 50ug; ribavirin 200mg;   - combination - 200mg+50µg (clearclick) - active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 80ug; ribavirin 200mg;   - combination - 200mg+80µg(clearclick) - active: peginterferon alfa-2b 80ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

Canada - English - Health Canada

merck canada inc - peginterferon alfa-2b - powder for solution - 74mcg - peginterferon alfa-2b 74mcg - interferons

Canada - English - Health Canada

merck canada inc - peginterferon alfa-2b - powder for solution - 118.4mcg - peginterferon alfa-2b 118.4mcg - interferons

Canada - English - Health Canada

merck canada inc - peginterferon alfa-2b - powder for solution - 177.6mcg - peginterferon alfa-2b 177.6mcg - interferons

Canada - English - Health Canada

merck canada inc - peginterferon alfa-2b - powder for solution - 222mcg - peginterferon alfa-2b 222mcg - interferons

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corp - peginterferon alfa-2a (40 kd) - solution for subcutaneous injection - 135mcg/0.5ml

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corp - peginterferon alfa-2a (40 kd) - solution for subcutaneous injection - 180mcg/0.5ml

Canada - English - Health Canada

hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons